Additionally, SRC-1 was shown to elevate glioblastoma stemness by modulating the XIST/miR-152/KLF4 axis, which provided a new diagnostic and therapeutic biomarker for glioblastomas (Fig. 3F) (Gong et al. 2021). Here, KLF4 is linked to glioblastoma.